UNASSIGNED: We aimed to investigate the efficacy of the MTCK in patients who are unable to delay ejaculation.
UNASSIGNED: Inclusion criteria were 20- to 60-year-old men feeling distressed and frustrated by PE and who had the same sexual partners throughout the study period. Exclusion criteria were neurologic disease and uncontrolled diabetes mellitus, as well as the use of antidepressants, α-blockers, and 5α-reductase inhibitors. The protocol comprised an 8-week training period with the MTCK from level 1 to level 5, with each level used twice before moving to the next level.
UNASSIGNED: The main outcome measure was the extension of intravaginal ejaculation latency time (IELT). The secondary outcome measures were score improvements on the Premature Ejaculation Diagnostic Tool, Sexual Health Inventory for Men, Erection Hardness Score, and Difficulty in Performing Sexual Intercourse Questionnaire-5.
UNASSIGNED: We enrolled 37 patients, and after 19 patients withdrew, 18 concluded the study without experiencing any adverse events. The mean patient age was 39.9 years. Geometric IELT after the 8-week training with the MTCK increased significantly (mean ± SE; 232.10 ± 72.16 seconds) vs baseline (103.91 ± 50.61 seconds, P = .006). Mean scores on the Premature Ejaculation Diagnostic Tool, Difficulty in Performing Sexual Intercourse Questionnaire-5, and Erection Hardness Score after 8-week training improved significantly vs the baseline values. The mean score on the Sexual Health Inventory for Men did not improve significantly after the 8-week training, but domain 1 did significantly improve after 8 weeks of MTCK use.
UNASSIGNED: The MTCK may be one possible treatment option for patients who are unable to delay ejaculation.
UNASSIGNED: This is the first study to show that the MTCK is effective for patients who are unable to delay ejaculation. A major limitation is that the present study was not strictly limited to an IELT <3 minutes.
UNASSIGNED: The MTCK may offer benefits not only for delay of ejaculation but also for erectile function.
■我们旨在研究MTCK对无法延迟射精的患者的疗效。
纳入标准是20至60岁的男性对PE感到苦恼和沮丧,并且在整个研究期间都有相同的性伴侣。排除标准是神经系统疾病和未控制的糖尿病,以及抗抑郁药的使用,α-阻断剂,和5α-还原酶抑制剂。该协议包括8周的训练期,MTCK从1级到5级,每个级别在移动到下一个级别之前使用两次。
■主要结局指标是阴道内射精潜伏期(IELT)的延长。次要结果指标是早泄诊断工具的评分改善,男性性健康清单,安装硬度评分,和执行性交问卷的难度-5。
■我们招募了37名患者,19名患者退出后,18结束了研究,没有经历任何不良事件。患者平均年龄为39.9岁。用MTCK进行8周训练后的几何IELT显着增加(平均值±SE;232.10±72.16秒)与基线(103.91±50.61秒,P=.006)。早泄诊断工具的平均得分,与基线值相比,进行性交问卷-5的难度和8周训练后的勃起硬度评分显着改善。8周训练后,男性性健康量表的平均得分没有显着改善,但域1在MTCK使用8周后确实显著改善。
■对于无法延迟射精的患者,MTCK可能是一种可能的治疗选择。
■这是第一项表明MTCK对无法延迟射精的患者有效的研究。主要限制是本研究不严格限于IELT<3分钟。
■MTCK不仅可以为射精延迟提供益处,还可以为勃起功能提供益处。